key: cord-0933917-ail4gr0b authors: Song, Tong; Yuan, Su; Yuan, Yu; Chuangyan, Wu; Jiuling, Chen; Sihua, Wang; Jinjun, Jiang title: Ribavirin Therapy For Severe COVID-19: A Retrospective Cohort Study date: 2020-07-23 journal: Int J Antimicrob Agents DOI: 10.1016/j.ijantimicag.2020.106114 sha: 19acde54e2be614b91ecc9d8a18c50fd3e2f33ca doc_id: 933917 cord_uid: ail4gr0b BACKGROUND: We aimed to compare ribavirin therapy for patients with severe COVID-19 with a supportive therapy only. PATIENTS AND METHODS: We retrospectively collected 115 patients with laboratory-confirmed COVID-19. All patients received supportive care and regular laboratory and clinical monitoring. We analyzed 44 patients who received intravenous ribavirin (treatment group) and 71 who did not (control group). RESULTS: Baseline laboratory and clinical characteristics were similar between groups, the negative conversion time for SARS-CoV2 test in ribavirin group was 12.8 ± 4.1 days compared with 14.1 ± 3.5 days in control group (P = 0.314). 7 (15.9%) of 44 patients in the ribavirin group had died, compared with 17 (23.9%) of 71 in the control group (P = 0.475). Adverse effects were similar between two groups. CONCLUSION: In patients with severe COVID-19, ribavirin therapy is not associated with improved negative conversion time for SARS-CoV2 test, and not associated with improved mortality rate. Further assessment in designed randomized, controlled trials is recommended. The world is concerned about the 2019 novel CoV (SARS-CoV2) and Coronavirus Disease 2019 (COVID-19), which was first discovered in Wuhan, China in December 2019. The patients showed respiratory diseases and severe pneumonia. Since then, the number of cases has been increasing. As of early April 2020, more than 9,000 cases and more than 3,000 deaths have been reported in China alone, and more than 950,000 cases in other countries. The treatment of patients with COVID-19 consists of supplemental oxygen, admit to an isolation ward, supportive care, antimicrobial therapy, and respiratory support [1, 2] . To date, no antiviral therapy has been approved for the treatment of COVID-19. Several therapeutic interventions for coronaviruses infection were studied during the outbreaks of SARS-CoV and MERS-CoV infection [3, 4] . Reviews of the literature suggest that ribavirin might be of benefit in patients with coronaviruses infection [4] . However, other studies have shown that ribavirin may not improve outcomes [5, 6] . In addition, ribavirin have potential adverse effects [7] , so the clinical use should be carefully weighed. We aimed to evaluate and compare the efficacy of ribavirin in the treatment of Severe COVID-19 Pneumonia. This single-center, retrospective cohort study included patients who were diagnosed with laboratory-confirmed SARS-CoV2 infection in Union Hospital, Tongji Medical College, Huazhong University of Science and Technology from January, 2020 to February, 2020. The study was approved by the Ethics Commission of Union Hospital (2020-0039). Due to the rapid emergence of this infectious disease, written informed consent was waived. When RT-PCR was positive in respiratory tract samples, SARS-CoV2 infection was confirmed. Two RT-PCR tests were used for SARS-CoV2 diagnostic confirmation. Nucleocapsid protein (N) and open reading frame 1ab (ORF1ab) were amplified during RT-PCR tests [8] . The excluding criteria included: 1) age younger than 18 or older than 80 years old; 2) transferred to another hospital (After the first consultation, some patients with special medical insurance types were transferred to the corresponding hospitals for treatment). The severe patients met any of the following condition:1) oxygen saturation ≤93% at rest state; 2) respiratory rate ≥30 breaths per minute; 3) arterial oxygen tension (PaO2)/inspiratory oxygen fraction (FiO2) ≤300 mmHg [9] . We defined patients who were received intravenous ribavirin (500mg, every 12 h, Zhengzhou cheuk-fung pharmaceutical CO., LTD) as the experimental group, and those who was not given intravenous ribavirin therapy as the control group. The control group received no other potential anti-viral treatments. All patients received appropriate antimicrobial therapy and supportive care. In addition to routine clinical monitoring, liver enzymes, renal function, electrolytes, and blood cell counts are assessed regularly throughout the course of treatment. The outcomes for the study were the negative conversion time for SARS-CoV2 test and mortality rate in different group. Continuous variables were expressed as mean ± standard, and categorical variables were provided as percentages (%). The chi-square tests and t tests were used to determine any statistical difference between the proportions and means of the two groups. Single-factor analysis was used for comparison clinical or laboratory features in different groups. Univariate and multiple logistic regression models were used to evaluate the associations between the patients with ribavirin or not and risk of death. All of the analyses were performed with EmpowerStats (http://www.empowerstats.com, X&Y Solutions, Inc., Boston, MA) and the statistical software packages R (http://www.R-project.org, The R Foundation). P values less than 0.05 (two-sided) were considered statistically significant. 134 individuals were diagnosed with severe COVID-19 between January, 2020 to February, 2020. Baseline characteristics were similar between patients who received ribavirin and those who did not. After excluding ineligible patients, 115 patients were included in the study: 71 in the control group and 44 in the treatment group ( Figure 1 ). The mean age of all 115 patients was 54.9 years (SD 15.1), and 62 (53.9%) were men ( Table 1) The treatment group was well tolerated and there were no early discontinuations due to adverse effects. There were no significant differences in laboratory characteristics (hemoglobin, leukocyte count, lymphocyte count, C-reactive protein, platelet count, creatinine, blood urea nitrogen, alanine transaminase and aspartate transaminase) between the two groups after ribavirin treatment course (Table 3) . With the global epidemic of the COVID-19, there is an urgent need for effective therapeutic intervention in patients with severe SARS-CoV2 infection. Our study shows that ribavirin is not associated with reduced time to PCR-negative conversion time for SARS-CoV2 test and does not provide survival benefit compared with control treatment. In our study, treatment with ribavirin was well tolerated. Anemia is a common complication in ribavirin therapy and has been shown in previous studies investigating the treatment of MERS-CoV and SARS-CoV infection [4, 10] . The degree of change in hemoglobin values during admission was 5.3 g/L in treatment group and 10.4 g/L in control group. There was no statistical difference between those two groups (p =0.051). In addition, there were no interruptions in treatment due to anemia. Whether to use ribavirin treatment was based on the doctor's clinical experience. Moreover, during a special period of the peak of the outbreak, the ribavirin was sometimes out of stock, which also may lead to treatment without ribavirin. Although patients use ribavirin or not was not completely random, no statistically significant differences in clinical characteristics (included medical history, demographic data, physical examination, and hematological, biochemical and radiological results) or support measures (immunoglobulin therapy, ventilation support and corticosteroid therapy) between the ribavirin group and control group, which makes it is comparable between treatment and control group. It was thought that ribavirin might be useful for treating coronavirus infection because of its broad-spectrum inhibition of RNA viruses. Several studies showed that ribavirin has useful activity against SARS-CoV in vitro [11, 12] . However, other studies have found ribavirin not to inhibit the virus in vivo, and did not promote the recovery of patients infected with SARS-CoV [13, 14] . A retrospective cohort study showed ribavirin and interferon alfa-2a therapy improved survival at 14 days, but not at 28 days in patients with severe MERS-CoV infection [4] . It should also be pointed out that a large multi-center retrospective study on different types of interferon with ribavirin to treat critically ill MERS cases did not improve survival [6] . Therefore, we should reconsider to remove the suggestion that patients with Covid-19 be treated with ribavirin. Our research is limited by its single-center, retrospective and non-randomized nature. Inevitably, selection bias cannot be completely ruled out. Incontrovertibly, new interventions should be evaluated in randomized, controlled clinical trials. However, such an approach is generally accepted in emerging diseases such as SARS-CoV2 infection. In addition, the sample size required to achieve 90% power of test is approximately 1048 patients. Our sample size is limited, and it is possible that we missed small effects. Nevertheless our results can provide a reference for further studies based on larger sample size randomized clinical trial or other populations. In conclusion, severe COVID-19 is associated with relatively high mortality rate. Intravenous ribavirin therapy is not associated with improved negative conversion Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan The Clinical and Chest CT Features Associated with Severe and Critical COVID-19 Pneumonia Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients We thank all patients and their families involved in the study.